|
ADVANCED TECHNOLOGY FOR ASSAYING CANCER-DRUG RESISTANCE
|
5R44CA114126-03
|
$419,983
|
$209,992
|
Lim, Mark
|
AMBERGEN, INC
|
|
Multiplex Detection of Mutations in Leukemia Patients
|
2R44CA130501-02
|
$609,861
|
$304,931
|
YE, FEI
|
AMBION DIAGNOSTICS, INC.
|
|
NR4A Nuclear Receptor Function in Leukemia
|
3R01CA111411-04S1
|
$25,519
|
$25,519
|
CONNEELY, ORLA
|
BAYLOR COLLEGE OF MEDICINE
|
|
NR4A Nuclear Receptor Function in Leukemia
|
5R01CA111411-04
|
$258,529
|
$258,529
|
CONNEELY, ORLA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Oncogene-Induced Evasion from Apoptosis
|
5R01CA105306-05
|
$318,352
|
$318,352
|
KHOSRAVI-FAR, ROYA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Novel Strategies for Treatment of Myeloproliferative Disorders
|
5R01CA131664-02
|
$352,750
|
$352,750
|
KHOSRAVI-FAR, ROYA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-20S2
|
$70,196
|
$1,404
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-20S3
|
$99,890
|
$1,998
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-20
|
$4,865,452
|
$97,309
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia
|
1R01CA139032-01
|
$332,000
|
$166,000
|
Muschen, Markus
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Rac GTPases as Targets in Lymphomagenesis
|
5R01CA125658-03
|
$285,000
|
$285,000
|
ZHENG, YI
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
Resistance of CML Stem Cells to Imatinib (Gleevec)
|
5R01CA095684-06
|
$320,589
|
$320,589
|
BHATIA, RAVI
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-26S1
|
$94,753
|
$13,265
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-26S2
|
$107,415
|
$15,038
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-26S3
|
$100,000
|
$14,000
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
5P30CA033572-26
|
$2,342,475
|
$327,947
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
City of Hope Lymphoma SPORE
|
3P50CA107399-05S1
|
$1,079,832
|
$269,958
|
forman, stephen
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletion
|
1R01CA138858-01
|
$329,202
|
$329,202
|
Saunthararajah, Yogen
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Role of Dok-1 in oncogenic tyrosine kinase signaling
|
1R01CA135053-01A1
|
$348,600
|
$348,600
|
VAN AELST, LINDA
|
COLD SPRING HARBOR LABORATORY
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S1
|
$124,531
|
$1,245
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S2
|
$100,000
|
$1,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S5
|
$143,383
|
$1,434
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-45
|
$11,688,901
|
$116,889
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Ex Vivo Alloanergization to Improve Immunity After Haploidentical Transplant
|
1R21CA137645-01A1
|
$370,550
|
$370,550
|
GUINAN, EVA
|
DANA-FARBER CANCER INSTITUTE
|
|
Signaling and targeting of FGFR1 fusions in 8p11 myeloproliferative syndrome
|
5R01CA120272-04
|
$263,700
|
$263,700
|
Chen, Jing
|
EMORY UNIVERSITY
|
|
FASEB Conference-Hematological Malignancies
|
5R13CA117424-03
|
$9,710
|
$2,428
|
ZHANG, DONG-ER
|
FEDERATION OF AMER SOC FOR EXPER BIOLOGY
|
|
Cancer Center Support Grant (Comprehensive)
|
2P30CA015704-35
|
$10,977,925
|
$109,779
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-35S3
|
$249,999
|
$2,500
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-35S4
|
$85,601
|
$856
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-35S5
|
$100,000
|
$1,000
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Integrating Diagnostics with Therapeutic Strategies in Chronic Myeloid Leukemia
|
1R01CA140371-01
|
$365,200
|
$365,200
|
Oehler, Vivian
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
CD45 Pretargeted Radioimmunotherapy for AML
|
2R01CA109663-05A1
|
$318,935
|
$63,787
|
Press, Oliver
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-11S1
|
$126,002
|
$20,160
|
DALTON, WILLIAM
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-11S2
|
$194,877
|
$31,180
|
Dalton, William
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
5P30CA076292-11
|
$3,021,607
|
$483,457
|
DALTON, WILLIAM
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
|
5R01CA129952-02
|
$287,173
|
$287,173
|
EPLING-BURNETTE, Pearlie K
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Phosphatase Targets of Lenalidomide in Myelodysplastic Syndrome
|
5R01CA131076-02
|
$436,029
|
$436,029
|
LIST, ALAN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Reactivating Apoptosis in Refractory Cancer by Selective Targeting of MCL-1
|
1F31CA144566-01
|
$32,232
|
$32,232
|
Stewart, Michelle
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
|
Novel Inhibitors for the Treatment of Highly Drug-Resistant Chronic Myelogenous
|
1R43CA139771-01
|
$149,616
|
$149,616
|
HOUSEY, GERARD
|
HOUSEY PHARMACEUTICAL RESEARCH LAB
|
|
Towards a Mouse Model of Classical Hodgkin's Disease and PTLD
|
2R01CA098285-06A1
|
$487,828
|
$243,914
|
RAJEWSKY, KLAUS
|
IMMUNE DISEASE INSTITUTE, INC.
|
|
International Symposium on Juvenile Myelomonocytic Leukemia
|
5R13CA132568-03
|
$5,000
|
$5,000
|
Loh, Mignon
|
JMML FOUNDATION
|
|
Telomere Shortening and Stem Cell Maintenance
|
5K08CA118416-04
|
$140,010
|
$140,010
|
ARMANIOS, MARY
|
JOHNS HOPKINS UNIVERSITY
|
|
Program on Molecular and Cellular Mechanisms of Tumorigenesis
|
5P01CA016519-34
|
$1,922,663
|
$192,266
|
BOEKE, Jef
|
JOHNS HOPKINS UNIVERSITY
|
|
Mechanism of combined 'epigenetic therapy' in myeloid malignancies
|
5R01CA125635-03
|
$486,728
|
$243,364
|
GORE, STEVEN
|
JOHNS HOPKINS UNIVERSITY
|
|
Bone Marrow Transplantation in Human Disease
|
5P01CA015396-34
|
$3,012,562
|
$602,512
|
JONES, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
|
Hematopoietic Stem Cells for Transplantation
|
5P01CA070970-11
|
$2,096,756
|
$629,027
|
SHARKIS, SAUL
|
JOHNS HOPKINS UNIVERSITY
|
|
Nostalgia in the WNT signaling pathway; fatty acids, epigenetics and leukemia
|
5R03CA129790-02
|
$70,000
|
$70,000
|
SOLLARS, VINCENT
|
MARSHALL UNIVERSITY
|
|
Genetic Analysis of Myeloproliferative Disease
|
5R01CA076167-08
|
$286,425
|
$286,425
|
COWELL, JOHN
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
|
MYELOPROLIFERATIVE DISORDERS RESEARCH CONSORTIUM
|
5P01CA108671-04
|
$4,738,076
|
$4,738,076
|
Hoffman, Ronald
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
|
Relapse after Allogeneci Hematopoietic Stem Cell Transplantation
|
ZIA BC 011239
|
$167,837
|
$151,053
|
Bishop, Michael
|
CCR (NCI)
|
Total relevant funding to Chronic Myeloproliferative Disorders for this search: $32,529,168
|